1Blumenachein GR Jr,Gatzemeier U,Fossella F,et al.Phase Ⅱ,multicenter,uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory advanced non-small-cell lung cancer.J Clin Oncol,2009,27:4274-4280.
3Lara PN Jr,Redman MW,Kelly K,et al.Disease control rate at 8weeks predicts clinical benefit in advanced non-small-cell lung cancer:results from South Oncology Group ratimized trials.J Clin Oncol,2008,26:463-467.